Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

IGF-I and IGFBP-3 Polymorphisms in Relation to Circulating Levels among African American and Caucasian Women

Aimee A. D'Aloisio, Jane C. Schroeder, Kari E. North, Charles Poole, Suzanne L. West, Gregory S. Travlos and Donna D. Baird
Aimee A. D'Aloisio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane C. Schroeder
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kari E. North
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Poole
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suzanne L. West
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory S. Travlos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donna D. Baird
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-08-0856 Published March 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Estimated differences from mean plasma IGFBP-3 levels associated with IGFBP-3 diplotypes for premenopausal Caucasian and African American women based on race-specific linear regression models of each IGFBP-3 diplotype group on plasma IGFBP-3 levels. Posterior medians (95% posterior limits) were estimated using empirical-Bayes method of information-weighted averaging by assuming a prior mean of 0 and a prior variance (Caucasians 174,161 and African Americans 186,819) corresponding to 1 SD of mean plasma IGFBP-3 (2 * SD / 3.92)2. For Caucasian models, group 1 includes n = 370 and group 2 includes n = 391. For African American models, group 1 includes n = 539, group 2 includes n = 563, and group 3 includes n = 547. Shaded area, ±200 ng/mL, which is ∼5% of the mean plasma IGFBP-3 levels (Caucasians group 1: 4,661 ng/mL and group 2: 4,587 ng/mL; African Americans group 1: 4,327 ng/mL, group 2: 4,060 ng/mL, and group 3: 4,106 ng/mL) for each reference diplotype.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Estimated differences from mean plasma IGF-I levels associated with IGF-I diplotypes for premenopausal Caucasian and African American women based on race-specific linear regression models of each IGF-I diplotype group on plasma IGF-I levels. Posterior medians (95% posterior limits) were estimated using empirical-Bayes method of information-weighted averaging by assuming a prior mean of 0 and a prior variance (Caucasians 901 and African Americans 1,419) corresponding to 1 SD of mean plasma IGF-I (2 * SD / 3.92)2. For Caucasian models, group 1 includes n = 394, group 2 includes n = 393, group 3 includes n = 389, and group 4 includes n = 393. For African American models, group 1 includes n = 565, group 2 includes n = 558, group 3 includes n = 545, and group 4 includes n = 565. Shaded area, ±10% of the mean plasma IGF-I levels (Caucasians group 1: 171 ng/mL, group 2: 173 ng/mL, group 3: 165 ng/mL, and group 4: 172 ng/mL; African Americans group 1: 166 ng/mL, group 2: 162 ng/mL, group 3: 166 ng/mL, and group 4: 162 ng/mL) for each reference diplotype.

Tables

  • Figures
  • Additional Files
  • Table 1.

    Characteristics of premenopausal Caucasian and African American women with genotype information from NIEHS UFS

    CharacteristicsCaucasians (n = 402), n (%)African Americans (n = 582), n (%)
    Age (y)
        35-39137 (34.1)219 (37.6)
        40-44135 (33.6)205 (35.2)
        ≥45130 (32.3)158 (27.1)
    Education
        High school12 (3.0)121 (20.8)*
        Some postsecondary33 (8.2)265 (45.5)
        College degree133 (33.1)123 (21.1)
        Graduate degree217 (54.0)68 (11.7)
        Missing7 (1.7)5 (0.9)
    Current oral contraceptives†37 (9.2)28 (4.8)
    Parity
        0236 (58.7)120 (20.6)
        154 (13.4)134 (23.0)
        291 (22.6)194 (33.3)
        ≥321 (5.2)134 (23.0)
    Body mass index
        Underweight-normal weight (<25)236 (58.7)147 (25.3)
        Overweight (25 to <30)95 (23.6)178 (30.6)
        Obese (≥30)71 (17.7)257 (44.2)
    Smoking status
        Current smoker31 (7.7)172 (29.6)
        Former smoker139 (34.6)133 (22.9)
        Never smoked232 (57.7)277 (47.6)
    Alcohol intake (past year)
        <0.5 drinks/wk60 (14.9)300 (51.5)
        ≥0.5 drinks/wk314 (78.1)245 (42.1)
        Missing28 (7.0)37 (6.4)

    Mean (SD)
    Mean (SD)
    Plasma IGF-I (ng/mL)†172 (58.7)165 (74.0)
    Plasma IGFBP-3 (ng/mL)†4,524 (822.3)4,085 (859.7)
    • ↵* Includes 11 women with less than high school education.

    • ↵† n missing: oral contraceptives: 3 Caucasians and 4 African Americans; Plasma IGF-I and IGFBP-3: 1 Caucasian and 8 African Americans.

  • Table 2.

    Estimated mean differences in plasma IGFBP-3 levels associated with IGFBP-3 SNP variants relative to estimated mean IGFBP-3 levels for reference genotypes (italicized) based on linear regression models for premenopausal Caucasian and African American women

    IGFBP-3 SNP*IGFBP-3 locationCaucasians
    African Americans
    LD block†Diplotype group (position)†MAF (%)‡Genotypen§Mean differences or means, ng/mL (95% CI)∥LD block†Diplotype group (position)†MAF (%)‡Genotypen§Mean differences or means, ng/mL (95% CI)∥
    rs903889Upstream11 (1)22.0GG22−398 (−754 to −42)Outside1 (1)9.4GT, GG97−131 (−318 to 55)
    GT131−67 (−240 to 106)
    TT2464,572 (4,470-4,674)TT4714,108 (4,031-4,185)
    rs924140Upstream1—46.8TT82581 (352-810)1—38.9CC95−560 (−761 to −360)
    CT210375 (190-560)CT251−276 (−427 to −125)
    CC1074,210 (4,059-4,361)TT2224,304 (4,194-4,414)
    rs2854744Upstream11 (2)46.3AA79592 (364-819)11 (2)42.2CC107−534 (−728 to −339)
    AC204353 (170-536)AC258−258 (−412 to −105)
    CC1074,221 (4,073-4,370)AA1954,305 (4,190-4,421)
    rs2854746Exon 111 (3)41.7CC65631 (398-864)11 (3)32.1CC52897 (656-1,138)
    CG203379 (206-551)CG259458 (318-598)
    GG1304,226 (4,091-4,360)GG2563,798 (3,699-3,897)
    rs2471551Intron 111 (4)19.4CC17−345 (−745 to 55)11 (4)20.3CC27−465 (−796 to −133)
    CG119−119 (−296 to 57)CG173−258 (−412 to −105)
    GG2604,583 (4,484-4,682)GG3644,193 (4,106-4,280)
    rs9282734Exon 2——0.4AC3698 (−233 to 1,629)—1 (5)3.3AC, CC3624 (−263 to 311)
    AA3934,520 (4,439-4,601)AA5324,079 (4,007-4,151)
    rs2453837Intron 3——0GG3974,524 (4,444-4,605)——0GG5684,083 (4,012-4,154)
    rs6953668Intron 3——0.6AG5394 (−330 to 1,119)11 (6)5.0AG, AA55−124 (−362 to 115)
    GG3944,522 (4,441-4,603)GG5134,094 (4,020-4,169)
    rs3110697Intron 311 (5)41.4AA62−425 (−670 to −181)Outside1 (7)36.1AA78−551 (−764 to −338)
    AG203−188 (−366 to −10)AG251−365 (−513 to −217)
    GG1314,693 (4,554-4,832)GG2384,325 (4,219-4,431)
    rs2453840Intron 421 (6)18.3AA12−535 (−1,008 to −62)22 (1)9.2AC, AA98209 (24-394)
    AC121−45 (−221 to 131)
    CC2634,560 (4,461-4,658)CC4704,045 (3,969-4,122)
    rs2453839Intron 42—20.1CC14−325 (−760 to 111)22 (2)40.9CC93−167 (−380 to 45)
    CT131−114 (−285 to 57)CT279−28 (−186 to 129)
    TT2504,574 (4,474-4,675)TT1944,130 (4,009-4,251)
    rs6670Exon 5; 3′ untranslatedOutside2 (1)21.2AA1274 (−402 to 551)33 (1)12.6AT, AA133−44 (−210 to 121)
    AT14579 (−90 to 249)
    TT2404,494 (4,390-4,598)TT4344,100 (4,020-4,180)
    rs13223993DownstreamOutside2 (2)21.4AA1939 (−343 to 421)33 (2)43.6AA116−17 (−216 to 182)
    AG13142 (−131 to 216)AG264−147 (−308 to 14)
    GG2444,522 (4,419-4,624)GG1844,163 (4,039-4,286)
    rs2270628Downstream32 (3)21.0TT15−316 (−743 to 112)43 (3)36.2TT8384 (−131 to 300)
    CT137−15 (−186 to 156)CT247−64 (−218 to 90)
    CC2474,544 (4,441-4,646)CC2364,101 (3,991-4,211)
    rs12671457Downstream32 (4)16.5AC, CC118−119 (−296 to 59)43 (4)5.1AC, CC55−218 (−456 to 21)
    AA2674,558 (4,460-4,657)AA5104,106 (4,032-4,181)
    • ↵* Represent tag SNPs except for 3 SNPs that were selected a priori: rs2854744 (-202 A/C), rs2854746 (Ala32Gly), and rs9282734 (His158Pro).

    • ↵† LD blocks consist of SNPs with MAF ≥ 5% in strong LD (95% of pairwise SNP comparisons with one-sided 95% CIs for D′ within 0.70-0.98). Group refers to SNP combination for diplotype estimation; position refers to SNP order in each group. SNPs were excluded from diplotype estimation based on the Tagger algorithm (r2 ≥ 0.8) or MAF < 5% for tag SNPs or MAF < 3% for SNPs selected a priori.

    • ↵‡ Based on total n = 402 (Caucasians) and total n = 582 (African Americans).

    • ↵§ Caucasians: n = 401, excluded 1 missing plasma IGFBP-3. African Americans: n = 574, excluded 8 missing plasma IGFBP-3.

    • ↵∥ Mean plasma IGFBP-3 levels for reference genotypes estimated from linear regression intercepts are italicized in the last row for each SNP. Mean differences in plasma IGFBP-3 levels for heterozygous and homozygous variants relative to reference genotypes were estimated from β values in linear regression models.

  • Table 3.

    Estimated mean differences in plasma IGF-I levels associated with IGF-I SNP variants relative to estimated mean IGF-I levels for reference genotypes (italicized) based on linear regression models for premenopausal Caucasian and African American women

    IGF-I SNP*IGF-I locationCaucasians
    African Americans
    LD block†Diplotype group (position)†MAF (%)‡Genotypen§Mean differences or means, ng/mL (95% CI)∥LD block†Diplotype group (position)†MAF (%)‡Genotypen§Mean differences or means, ng/mL (95% CI)∥
    rs35767UpstreamOutside1 (1)16.0AG, AA1165 (−7 to 18)11 (1)40.8AA99−1 (−19 to 17)
    AG264−2 (−16 to 11)
    GG280171 (164-177)GG205166 (156-176)
    rs5742612Upstream——3.9AG, GG3021 (−1 to 42)——3.3AG, GG355 (−20 to 31)
    AA368171 (165-177)AA536164 (158-171)
    rs5742614Intron 1——1.8CG1418 (−14 to 49)11 (2)11.5CG, CC1248 (−6 to 23)
    GG385172 (166-178)GG444163 (156-170)
    rs3729846Exon 2——0——0.8CT933 (−16 to 82)
    CC399172 (166-178)CC557164 (158-170)
    rs12821878Intron 212 (1)22.7AA210 (−26 to 27)Outside1 (3)5.8AG, AA64−15 (−34 to 5)
    AG1395 (−8 to 17)
    GG237171 (163-178)GG505167 (160-173)
    rs10860869Intron 21—29.1TT31−5 (−28 to 17)Outside2 (1)32.3TT5911 (−10 to 32)
    AT1706 (−6 to 18)AT24912 (−1 to 25)
    AA196170 (162-179)AA262158 (149-167)
    rs1019731Intron 212 (2)12.3AC, AA9310 (−4 to 23)——3.4AC39−10 (−34 to 14)
    CC304170 (164-177)CC528165 (159-172)
    rs7956547Intron 212 (3)27.3CC29−5 (−28 to 18)22 (2)26.2CC438 (−16 to 32)
    CT1602 (−10 to 14)CT21010 (−3 to 23)
    TT209172 (164-180)TT314160 (152-168)
    rs5742626Intron 2——0.5CT4−3 (−61 to 54)22 (3)7.2CT, CC78−8 (−26 to 9)
    TT394172 (166-178)TT491166 (159-173)
    rs17880975Intron 2——0.1AG1−78 (−193 to 37)——2.3AG268 (−21 to 38)
    GG395173 (167-178)GG540165 (158-171)
    rs2033178Intron 223 (1)6.2AG, AA475 (−13 to 22)——4.7AG, AA50−24 (−46 to −3)
    GG349172 (166-178)GG513167 (161-174)
    rs17884646Intron 2——0TT397172 (166-178)——0TT570165 (159-171)
    rs5742657Intron 2——2.2AG, GG1718 (−11 to 46)2—12.1AG, GG1283 (−11 to 18)
    AA383171 (166-177)AA440164 (157-170)
    rs5742663Intron 2——0.1GT112 (−103 to 127)2—11.6GT, GG1238 (−6 to 23)
    TT396172 (167-178)TT444163 (156-170)
    rs11829586Intron 2——2.3AG1816 (−12 to 43)2—11.5AG, AA1217 (−8 to 22)
    GG380172 (166-178)GG445163 (156-170)
    rs4764884Intron 22—25.7TT25−16 (−40 to 8)22 (4)23.7TT3410 (−16 to 36)
    CT1530 (−12 to 12)CT2005 (−8 to 18)
    CC218173 (165-181)CC333162 (154-170)
    rs5742683Intron 2——0.1AG112 (−102 to 127)2—10.6AG, GG1135 (−11 to 20)
    AA396172 (166-178)AA454164 (157-171)
    rs17884626Exon 3——0——1.0CT1113 (−31 to 57)
    CC399172 (167-178)CC559164 (158-171)
    rs5009837Intron 32—30.3TT36−6 (−27 to 15)Outside2 (5)41.3TT1058 (−9 to 26)
    CT1676 (−6 to 18)CT26010 (−3 to 24)
    CC192170 (162-178)CC203158 (148-168)
    rs17727841Intron 323 (2)19.1CC15−4 (−35 to 27)——4.7CG, CC4923 (1-44)
    CG123−4 (−17 to 8)
    GG261174 (167-181)GG520163 (156-169)
    rs4764883Intron 32—30.9CC37−8 (−29 to 12)3—45.8TT132−12 (−29 to 5)
    CT1674 (−8 to 17)CT248−11 (−25 to 3)
    TT186171 (163-179)CC180173 (162-183)
    rs9308315Intron 32—28.2AA28−16 (−39 to 7)33 (1)49.8TT150−12 (−28 to 5)
    AT1663 (−9 to 15)AT262−11 (−26 to 4)
    TT201172 (164-180)AA152173 (161-185)
    rs978458Intron 323 (3)28.0TT28−13 (−37 to 10)3—37.5TT839 (−10 to 28)
    CT1644 (−8 to 16)CT2597 (−6 to 20)
    CC202172 (163-180)CC224160 (151-170)
    rs5742692Intron 3——2.133 (2)11.7GG1114 (−31 to 58)
    AG1718 (−11 to 46)AG1114 (−12 to 19)
    AA382171 (166-177)AA444164 (157-170)
    rs11111262Intron 32—9.9AG, AA76−4 (−19 to 10)——2.7AG, AA2740 (11-68)
    GG321173 (167-180)GG536163 (157-169)
    rs1520220Intron 323 (4)19.1GG13−33 (−65 to 0)33 (3)34.7GG7310 (−9 to 29)
    CG1247 (−6 to 19)CG2506 (−7 to 19)
    CC258171 (164-178)CC245161 (151-170)
    rs3730204Exon 4; 3′ untranslated——2.3CT18−24 (−52 to 3)——0.3CT36 (−79 to 90)
    TT378173 (168-179)TT562165 (159-171)
    rs6214Exon 4; 3′ untranslatedOutside3 (5)39.8TT6717 (0-34)Outside3 (4)45.2CC124−3 (−20 to 14)
    CT183−2 (−14 to 11)CT263−4 (−18 to 10)
    CC148170 (161-180)TT178167 (156-178)
    rs6219Exon 4; 3′ untranslated34 (1)10.0CT, TT78−6 (−20 to 9)44 (1)9.1CT, TT9416 (−1 to 32)
    CC321174 (167-180)CC475162 (155-169)
    rs2946834Downstream34 (2)33.0AA39−7 (−28 to 13)44 (2)49.3AA14216 (0-33)
    AG1811 (−11 to 13)AG2792 (−12 to 17)
    GG175172 (164-181)GG147159 (147-171)
    • ↵* Represent tag SNPs except for 2 SNPs that were selected a priori: rs3729846 (Thr52Thr) and rs17884626 (Ala115Thr).

    • ↵† LD blocks consist of SNPs with MAF ≥ 5% in strong LD (95% of pairwise SNP comparisons with one-sided 95% CIs for D′ within 0.70-0.98). Group refers to SNP combination for diplotype estimation; position refers to SNP order in each group. SNPs were excluded from diplotype estimation based on either Tagger algorithm (r2 ≥ 0.8) or MAF < 5% for tag SNPs or MAF < 3% for SNPs selected a priori. For African Americans, rs9308315 was the substitute for rs4764883 (Hardy-Weinberg P < 0.01).

    • ↵‡ Based on total n = 402 (Caucasians) and total n = 582 (African Americans).

    • ↵§ Caucasians: n = 401, excluded 1 missing plasma IGF-I. African Americans: n = 574, excluded 8 missing plasma IGF-I.

    • ↵∥ Mean plasma IGF-I levels for reference genotypes estimated from linear regression intercepts are italicized in the last row for each SNP. Mean differences in plasma IGF-I levels for heterozygous and homozygous variants relative to reference genotypes were estimated from β values in linear regression models.

Additional Files

  • Figures
  • Tables
  • Supplementary Data, D'Aloisio, et al.

    Files in this Data Supplement:

    • Supplementary Tables 1-10
    • Supplementary Figure 1
    • Supplementary Figure 2
    • Supplementary Figure Legends
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 18 (3)
March 2009
Volume 18, Issue 3
  • Table of Contents
  • Table of Contents (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
IGF-I and IGFBP-3 Polymorphisms in Relation to Circulating Levels among African American and Caucasian Women
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
IGF-I and IGFBP-3 Polymorphisms in Relation to Circulating Levels among African American and Caucasian Women
Aimee A. D'Aloisio, Jane C. Schroeder, Kari E. North, Charles Poole, Suzanne L. West, Gregory S. Travlos and Donna D. Baird
Cancer Epidemiol Biomarkers Prev March 1 2009 (18) (3) 954-966; DOI: 10.1158/1055-9965.EPI-08-0856

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
IGF-I and IGFBP-3 Polymorphisms in Relation to Circulating Levels among African American and Caucasian Women
Aimee A. D'Aloisio, Jane C. Schroeder, Kari E. North, Charles Poole, Suzanne L. West, Gregory S. Travlos and Donna D. Baird
Cancer Epidemiol Biomarkers Prev March 1 2009 (18) (3) 954-966; DOI: 10.1158/1055-9965.EPI-08-0856
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Urinary Melatonin in Relation to Breast Cancer Risk
  • Endometrial Cancer and Ovarian Cancer Cross-Cancer GWAS
  • Risk Factors of Subsequent CNS Tumor after Pediatric Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement